Scholarlink

<p>The apolipoprotein E (<i>APOE</i>) gene is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), with the ε4 allele increasing risk and decreasing the average age of onset. While <i>APOE</i> genotyping is primarily used in research or clinical settings for patients with memory concerns, interest in disclosing <i>APOE</i> status to asymptomatic individuals—particularly during early adulthood—is growing. This trend is fueled by the rise of direct-to-consumer genetic testing and emerging prevention-focused clinical trials. However, ethical debates remain unresolved about the potential harms of early disclosure, including anxiety, stigma, and misunderstanding of probabilistic risk. Conversely, some argue that knowledge of <i>APOE</i> status could motivate beneficial lifestyle changes, inform reproductive decisions, and promote long-term planning. In this article, we explore the neuroethical implications of <i>APOE</i> genotype disclosure across the lifespan, with a particular focus on young adulthood—a time marked by identity formation, life planning, and increased receptivity to health behavior interventions. Drawing from neuroscience, bioethics, and behavioral genetics, we argue that disclosure is a double-edged sword: while it may offer psychological, behavioral, and economic benefits for some, it also raises significant concerns about autonomy, equity, and long-term psychosocial impact. We conclude by recommending age-sensitive, ethically grounded guidelines for <i>APOE</i> disclosure, calling for interdisciplinary research to better understand how individuals interpret and respond to genetic risk information throughout their lives.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Double-Edged Sword: Ethical and Psychological Implications of APOE Genotype Disclosure Across the Lifespan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Diego Iacono

摘要

The apolipoprotein E (APOE) gene is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), with the ε4 allele increasing risk and decreasing the average age of onset. While APOE genotyping is primarily used in research or clinical settings for patients with memory concerns, interest in disclosing APOE status to asymptomatic individuals—particularly during early adulthood—is growing. This trend is fueled by the rise of direct-to-consumer genetic testing and emerging prevention-focused clinical trials. However, ethical debates remain unresolved about the potential harms of early disclosure, including anxiety, stigma, and misunderstanding of probabilistic risk. Conversely, some argue that knowledge of APOE status could motivate beneficial lifestyle changes, inform reproductive decisions, and promote long-term planning. In this article, we explore the neuroethical implications of APOE genotype disclosure across the lifespan, with a particular focus on young adulthood—a time marked by identity formation, life planning, and increased receptivity to health behavior interventions. Drawing from neuroscience, bioethics, and behavioral genetics, we argue that disclosure is a double-edged sword: while it may offer psychological, behavioral, and economic benefits for some, it also raises significant concerns about autonomy, equity, and long-term psychosocial impact. We conclude by recommending age-sensitive, ethically grounded guidelines for APOE disclosure, calling for interdisciplinary research to better understand how individuals interpret and respond to genetic risk information throughout their lives.